FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615553099> ?p ?o ?g. }

• W2615553099 abstract "Neuroblastomas (NBs) exhibit heterogeneity and show clinically significant prognosis classified by genetic alterations. Among prognostic genes or genome factors, MYCN amplification (MNA) is the most established genomic marker of poor prognosis in patients with NB. However, the prognostic classification of more than 60% of patients without MNA has yet to be clarified. In this study, the application of target next-generation sequencing (NGS) was extended on the basis of a comprehensive panel of regions where copy number variations (CNVs) or point mutations occurred to improve the prognostic evaluation of these patients and obtain the sequence of 33 patients without MNA. A mean coverage depth of 887× was determined in the target regions in all of the samples, and the mapped read percentage was more than 99%. Somatic mutations in patients without MNA could be precisely defined on the basis of these findings, and 17 unique somatic aberrations, including 14 genes, were identified in 11 patients. Among these variations, most were CNVs with a number of 13. The 3-year event-free survival (EFS) of CNV(-) patients was 60.0% compared with the EFS (16.7%) of CNV(+) patients (P = 0.015, HR = 0.1344, 95%, CI = 0.027 to 0.678). CNVs were also associated with unfavorable histological characteristics (P = 0.003) and likely to occur in stage 4 (P = 0.041). These results might further indicate the role of CNVs in NB chemotherapy resistance (P = 0.059) and show CNVs as a therapeutic target. In multivariate analysis, the presence of CNVs was a clinically negative prognostic marker that impaired the outcome of patients without MNA and associated with poor prognosis in this tumor subset. Comprehensive genetic/genomic profiling instead of focusing on single genetic marker should be performed through in-depth NGS that could reveal prognostic information, improve NB target therapy, and provide a basis for investigations on NB pathogenesis." @default.
• W2615553099 created "2017-05-26" @default.
• W2615553099 creator A5005329167 @default.
• W2615553099 creator A5006655097 @default.
• W2615553099 creator A5008367011 @default.
• W2615553099 creator A5020748598 @default.
• W2615553099 creator A5022459197 @default.
• W2615553099 creator A5024994354 @default.
• W2615553099 creator A5025362555 @default.
• W2615553099 creator A5028259145 @default.
• W2615553099 creator A5029928652 @default.
• W2615553099 creator A5036519850 @default.
• W2615553099 creator A5041621047 @default.
• W2615553099 creator A5054119365 @default.
• W2615553099 creator A5068832650 @default.
• W2615553099 creator A5083186267 @default.
• W2615553099 creator A5085833014 @default.
• W2615553099 creator A5087388223 @default.
• W2615553099 date "2017-05-17" @default.
• W2615553099 modified "2023-09-26" @default.
• W2615553099 title "Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification" @default.
• W2615553099 cites W1483549288 @default.
• W2615553099 cites W1773647558 @default.
• W2615553099 cites W1802597807 @default.
• W2615553099 cites W1883334036 @default.
• W2615553099 cites W1899939340 @default.
• W2615553099 cites W1926885922 @default.
• W2615553099 cites W1969855459 @default.
• W2615553099 cites W1974818286 @default.
• W2615553099 cites W1994100376 @default.
• W2615553099 cites W1997727251 @default.
• W2615553099 cites W2007476455 @default.
• W2615553099 cites W2010111403 @default.
• W2615553099 cites W2010914889 @default.
• W2615553099 cites W2012219845 @default.
• W2615553099 cites W2015298173 @default.
• W2615553099 cites W2019137723 @default.
• W2615553099 cites W2024280594 @default.
• W2615553099 cites W2033037904 @default.
• W2615553099 cites W2035151755 @default.
• W2615553099 cites W2037670359 @default.
• W2615553099 cites W2049942970 @default.
• W2615553099 cites W2050979352 @default.
• W2615553099 cites W2066098786 @default.
• W2615553099 cites W2076984763 @default.
• W2615553099 cites W2079076968 @default.
• W2615553099 cites W2087911747 @default.
• W2615553099 cites W2091671160 @default.
• W2615553099 cites W2093144236 @default.
• W2615553099 cites W2095296988 @default.
• W2615553099 cites W2096398040 @default.
• W2615553099 cites W2099731590 @default.
• W2615553099 cites W2100985631 @default.
• W2615553099 cites W2101042741 @default.
• W2615553099 cites W2102118318 @default.
• W2615553099 cites W2103443623 @default.
• W2615553099 cites W2104320396 @default.
• W2615553099 cites W2108067333 @default.
• W2615553099 cites W2112612051 @default.
• W2615553099 cites W2116195296 @default.
• W2615553099 cites W2118071133 @default.
• W2615553099 cites W2131776400 @default.
• W2615553099 cites W2133351514 @default.
• W2615553099 cites W2134409560 @default.
• W2615553099 cites W2141439467 @default.
• W2615553099 cites W2142701568 @default.
• W2615553099 cites W2148846907 @default.
• W2615553099 cites W2154500564 @default.
• W2615553099 cites W2154655439 @default.
• W2615553099 cites W2157789221 @default.
• W2615553099 cites W2169310901 @default.
• W2615553099 cites W2253160634 @default.
• W2615553099 cites W2279013917 @default.
• W2615553099 cites W2330923897 @default.
• W2615553099 cites W2409517616 @default.
• W2615553099 doi "https://doi.org/10.18632/oncotarget.17917" @default.
• W2615553099 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5564799" @default.
• W2615553099 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28591696" @default.
• W2615553099 hasPublicationYear "2017" @default.
• W2615553099 type Work @default.
• W2615553099 sameAs 2615553099 @default.
• W2615553099 citedByCount "3" @default.
• W2615553099 countsByYear W26155530992018 @default.
• W2615553099 countsByYear W26155530992019 @default.
• W2615553099 countsByYear W26155530992021 @default.
• W2615553099 crossrefType "journal-article" @default.
• W2615553099 hasAuthorship W2615553099A5005329167 @default.
• W2615553099 hasAuthorship W2615553099A5006655097 @default.
• W2615553099 hasAuthorship W2615553099A5008367011 @default.
• W2615553099 hasAuthorship W2615553099A5020748598 @default.
• W2615553099 hasAuthorship W2615553099A5022459197 @default.
• W2615553099 hasAuthorship W2615553099A5024994354 @default.
• W2615553099 hasAuthorship W2615553099A5025362555 @default.
• W2615553099 hasAuthorship W2615553099A5028259145 @default.
• W2615553099 hasAuthorship W2615553099A5029928652 @default.
• W2615553099 hasAuthorship W2615553099A5036519850 @default.
• W2615553099 hasAuthorship W2615553099A5041621047 @default.
• W2615553099 hasAuthorship W2615553099A5054119365 @default.
• W2615553099 hasAuthorship W2615553099A5068832650 @default.
• W2615553099 hasAuthorship W2615553099A5083186267 @default.

• next